Published in Diabetes Week, April 24th, 2006
According to recent research from France, "The aim of this study was to demonstrate the superiority of benfluorex over placebo as an add-on therapy in type 2 diabetic patients in whom diabetes is insufficiently controlled by sulfonylurea monotherapy and who have a limitation for the use of metformin."
P. Moulin and colleagues working with Hopital Cardio-Vasculaire Louis Pradel explained, "Type 2 diabetic patients with HbA1C (A1C) ID (7-10%) who were receiving the maximum tolerated sulfonylurea...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.